Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia - Wikidata - wikimedia - TriplyDB

Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia

Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia

http://www.wikidata.org/entity/Q26783600

about

Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia

http://www.wikidata.org/entity/Q26783600

description

2015 nî lūn-bûn

@nan

2015 թուականին հրատարակուած գիտական յօդուած

@hyw

2015 թվականին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

name

Clinical utility and patient c ...... n chronic lymphocytic leukemia

@ast

Clinical utility and patient c ...... n chronic lymphocytic leukemia

@en

Clinical utility and patient c ...... n chronic lymphocytic leukemia

@nl

type

label

Clinical utility and patient c ...... n chronic lymphocytic leukemia

@ast

Clinical utility and patient c ...... n chronic lymphocytic leukemia

@en

Clinical utility and patient c ...... n chronic lymphocytic leukemia

@nl

prefLabel

Clinical utility and patient c ...... n chronic lymphocytic leukemia

@ast

Clinical utility and patient c ...... n chronic lymphocytic leukemia

@en

Clinical utility and patient c ...... n chronic lymphocytic leukemia

@nl

P1433

Q26783600-06992CEB-24A8-46DD-A902-87B77666E47C

P1476

Q26783600-0A1C5683-9DDC-4164-A2DA-9251B8A1F8F5

P2093

Q26783600-084BEEAD-971E-4E66-AD79-318508234EEE

Q26783600-78D70825-5E3A-49C8-862E-EE15E597FDE2

Q26783600-CFB4AA91-257F-4AA4-8C1A-1C885704EC41

Q26783600-FD129983-1DF2-4988-9DD7-4DC7A7C6E8EA

Q26783600-FDE91E00-EC14-470B-B196-F7EEA1510C47

P2860

Q26783600-01B4371C-F820-49B5-887B-6E1FEA4EE629

Q26783600-0F6667CE-1B47-4696-ADC1-B54B6111E1B5

Q26783600-14D3CA5F-4312-470E-95AF-751FD504D369

Q26783600-1824BB8C-5092-4A4E-ADA8-29E3BE8441B1

Q26783600-1BD79045-BEB4-4BD5-B116-F2D31FD5F820

Q26783600-1BEE7786-6969-41CB-B80D-32DC3BD3AE71

Q26783600-1C82CE8E-EEB0-47DE-B1A0-289AD8F8D80D

Q26783600-1EDEA5FE-D5BE-40F7-B256-DB24977FFF60

Q26783600-230CAC63-3AAB-4101-A2B0-A8C4D8E1771E

Q26783600-357B7A2F-C41D-4033-B5F4-7C832A4D6D6E

P304

Q26783600-EC7B100B-B0DA-4425-852D-6236256839C8

P31

Q26783600-D92F3361-6889-45A6-8464-B696D0AFD553

P356

Q26783600-69645CD0-CC7F-4A54-A811-6F74E5F99A98

P407

Q26783600-A4996F2A-9999-4DF3-B468-09E968693B34

P478

Q26783600-1CB811B9-E74C-4506-B0D6-A85443F3DF4F

P577

Q26783600-81E8F902-2E81-4C3B-B9E8-520509E648C0

P698

Q26783600-5B7DF9B0-3183-40CE-B141-09E02BE28E6F

P921

Q26783600-A85C705D-17FA-48F4-B7F2-4064CBDE9C5D

P932

Q26783600-17D2E433-2E60-4140-A0DE-BA447F1B05E1

P356

P1433

Biologics: Targets and Therapy

P1476

Clinical utility and patient c ...... n chronic lymphocytic leukemia

@en

P2093

Alessandra Tedeschi

http://www.w3.org/2001/XMLSchema#string

Anna Maria Frustaci

http://www.w3.org/2001/XMLSchema#string

Marco Montillo

http://www.w3.org/2001/XMLSchema#string

Paola Picardi

http://www.w3.org/2001/XMLSchema#string

Roberto Cairoli

http://www.w3.org/2001/XMLSchema#string

P2860

Rituximab: mechanism of action

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.

Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.

Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.

P304

75-86

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/BTT.S60503

http://www.w3.org/2001/XMLSchema#string

P407

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26425075

http://www.w3.org/2001/XMLSchema#string

P921

P932

4583123

http://www.w3.org/2001/XMLSchema#string